Trials / Active Not Recruiting
Active Not RecruitingNCT05879068
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
A Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of PM8002 Injection in Combination With Paclitaxel Injection as Second Line Treatment for Small Cell Lung Cancer(SCLC)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 99 (estimated)
- Sponsor
- Biotheus Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with paclitaxel as second line treatment for SCLC.
Detailed description
This is a phase II, single arm study assessing the efficacy and safety of PM8002 in combination with paclitaxel as second line treatment for SCLC who failed first-line platinum-based chemotherapy with or without checkpoint inhibitors therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PM8002 | IV infusion |
| DRUG | Paclitaxel | IV infusion |
Timeline
- Start date
- 2022-05-27
- Primary completion
- 2025-04-30
- Completion
- 2026-04-30
- First posted
- 2023-05-30
- Last updated
- 2024-12-18
Locations
11 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05879068. Inclusion in this directory is not an endorsement.